Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CB-002
- Development stage
- Preclinical
- Lead developer
- Cubed Biotech
- Modality
- Small Molecules
01
Overview
CB-002, also known as Ocelot, is a preclinical-stage small molecule novel chemical entity (NCE) being developed by Cubed Biotech. It belongs to a breakthrough class of non-hallucinogenic 5-HT2A receptor modulators derived from a proprietary hybrid tryptamine/phenylethylamine library. Designed to provide antidepressant and anxiolytic effects without the characteristic psychedelic experience associated with traditional 5-HT2A agonists, CB-002 is being investigated for Major Depressive Disorder (MDD), Anxiety Disorders, and Neurodegeneration. The program is currently advancing through early discovery toward IND-enabling studies.
- Other names
- Ocelot
02
Targets
HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on CB-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CB-002.